Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Has Average Price Target of $37.25

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $37.25.

Several research firms have weighed in on ZLAB. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Citigroup lifted their price target on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday.

Insider Transactions at Zai Lab

In other Zai Lab news, CEO Ying Du sold 7,026 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $18.53, for a total transaction of $130,191.78. Following the completion of the transaction, the chief executive officer owned 1,203,784 shares in the company, valued at approximately $22,306,117.52. This represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William Lis sold 8,506 shares of Zai Lab stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 16,411 shares of company stock valued at $365,337. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently bought and sold shares of ZLAB. Nykredit A S bought a new position in shares of Zai Lab during the 2nd quarter worth approximately $79,000. Headlands Technologies LLC raised its holdings in shares of Zai Lab by 142.0% in the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock valued at $1,292,000 after purchasing an additional 39,901 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its position in shares of Zai Lab by 74.7% in the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after purchasing an additional 58,158 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

Zai Lab Price Performance

ZLAB stock opened at $24.98 on Wednesday. The company has a 50 day moving average price of $23.80 and a 200 day moving average price of $20.98. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $34.72. The stock has a market capitalization of $2.84 billion, a PE ratio of -14.61 and a beta of 0.83.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $106.31 million during the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. As a group, equities analysts expect that Zai Lab will post -2.37 earnings per share for the current fiscal year.

Zai Lab Company Profile

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company’s research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections.